Electrocore
General Information | |
Business: |
We are a commercial-stage bioelectronic medicine company with a platform non-invasive vagus nerve stimulation therapy initially focused on neurology and rheumatology. Our therapy, gammaCore, has pharmacologic effects on the peripheral and central nervous systems, which modulate neurotransmitters and immune function. gammaCore is FDA-cleared for the acute treatment of pain associated with migraine and episodic cluster headache in adults.
|
Industry: | ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS |
Employees: | 64 |
Founded: | 2005 |
Contact Information | |
Address | 150 Allen Rd., Suite 201, Basking Ridge, NJ 07920, US |
Phone Number | (973) 290-0097 |
Web Address | http://www.electrocore.com |
View Prospectus: | Electrocore |
Financial Information | |
Market Cap | $426.4mil |
Revenues | $847.2 mil (last 12 months) |
Net Income | $-39.2 mil (last 12 months) |
IPO Profile | |
Symbol | ECOR |
Exchange | NASDAQ |
Shares (millions): | 5.2 |
Price range | $15.00 - $15.00 |
Est. $ Volume | $78.0 mil |
Manager / Joint Managers | Evercore ISI/ Cantor/ JMP Securities |
CO-Managers | BTIG |
Expected To Trade: | 6/22/2018 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |